Safety Trolls?: Generic Firms Seek To Invalidate Xyrem REMS Patent Via PTO
This article was originally published in The Pink Sheet Daily
Executive Summary
In a first by drug makers seeking covered business method patent review, Amneal, Par and Roxane petition PTO appeal board to cancel patent claims covering distribution of Jazz’s Xyrem.